Clinical cases of vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA vasculitis) induced by COVID-19

Abstract

COVID-19 is similar to immunoinflammatory rheumatic diseases in clinical manifestations, immune responses and pathogenetic mechanisms. Specific autoantibodies as markers of autoimmune diseases can be detected in patients with coronavirus infection. Most often, after COVID-19, antinuclear antibodies, antibodies to phospholipids, to cardiolipin, to β2-glycoprotein, to cytoplasmic antigens SS-A and SS/B, and cyclic citrulline-containing peptide are detected. In moderate and severe cases of COVID-19 infection with pulmonary-renal syndrome, cytokine storm, antineutrophil cytoplasmic antibodies, antibodies to myeloperoxidase and to proteinase 3 have become more frequent, which can trigger neutrophil NETosis with the formation of extracellular neutrophil traps — networks and induce the development of autoimmune processes and the appearance of de novo immunoinflammatory rheumatic diseases: arthritis , systemic lupus erythematosus, vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA vasculitis). Our study presents 4 clinical cases of patients with ANCA vasculitis with a history of recent coronavirus infection, chronologically verified. The average time after COVID-19 and the onset of ANCA vasculitis was about 3 months; damage to the upper respiratory tract, lower respiratory tract, skin and renal syndromes were observed. The severity of ANCA vasculitis did not depend on the severity of coronavirus infection: a mild course of COVID-19 infection did not exclude a severe course of ANCA vasculitis. It is recommended that all patients during and after coronavirus infection with post-COVID syndrome in the presence of damage to the ENT organs, kidneys, and skin are screened the presence of antineutrophil cytoplasmic antibodies to exclude the onset of ANCA vasculitis.

Keywords

COVID-19 / ANCA vasculit / antineutrophil cytoplasmic antibodies / antibodies to myeloperoxidase / antibodies to proteinase 3 / induction / onset

References

[1] Cavalli E, Bramanti A, Ciurleo R, et al. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review). Int J Mol Med. 2020;46(3):903–912. doi: 10.3892/ijmm.2020.4659

[2] Cavalli E., Bramanti A., Ciurleo R., et al. Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review) // Int J Mol Med. 2020. Vol. 46, N. 3. P. 903–912. doi: 10.3892/ijmm.2020.4659

[3] Bertin D, Brodovitch A, Beziane A, et al. Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity. Arthritis Rheumatol. 2020;72(11):1953–1955. doi: 10.1002/art.41409

[4] Bertin D., Brodovitch A., Beziane A., et al. Anticardiolipin IgG autoantibody level is an independent risk factor for COVID-19 severity // Arthritis Rheumatol. 2020. Vol. 72, N. 11. P. 1953–1955. doi: 10.1002/art.41409

[5] Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. doi: 10.1126/scitranslmed.abd3876

[6] Zuo Y., Estes S.K., Ali R.A., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 // Sci Transl Med. 2020. Vol. 12, N. 570. P. eabd3876. doi: 10.1126/scitranslmed.abd3876

[7] Hasan Ali O, Bomze D, Risch L, et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. Clin Infect Dis. 2021;73(9):e2869–e2874. doi: 10.1093/cid/ciaa1496

[8] Hasan Ali O., Bomze D., Risch L., et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies // Clin Infect Dis. 2021. Vol. 73, N. 9. P. e2869–e2874. doi: 10.1093/cid/ciaa1496

[9] Zebardast A, Hasanzadeh A, Ebrahimian Shiadeh SA, et al. COVID-19: A trigger of autoimmune diseases. Cell Biol Int. 2023;47(5):848–858. doi: 10.1002/cbin.11997

[10] Zebardast A., Hasanzadeh A., Ebrahimian Shiadeh S.A., et al. COVID-19: A trigger of autoimmune diseases // Cell Biol Int. 2023. Vol. 47, N. 5. P. 848–858. doi: 10.1002/cbin.11997

[11] Sharma C, Bayry J. High risk of autoimmune diseases after COVID-19. Nat Rev Rheumatol. 2023;19:399–400. doi: 10.1038/s41584-023-00964-y

[12] Sharma C., Bayry J. High risk of autoimmune diseases after COVID-19 // Nat Rev Rheumatol. 2023. Vol. 19. P. 399–400. doi: 10.1038/s41584-023-00964-y

[13] Chang R, Yen-Ting Chen T, Wang SI, et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study. EClinicalMedicine. 2023;56:101783. doi: 10.1016/j.eclinm.2022.101783

[14] Chang R., Yen-Ting Chen T., Wang S.I., et al. Risk of autoimmune diseases in patients with COVID-19: A retrospective cohort study // EClinicalMedicine. 2023. Vol. 56. P. 101783. doi: 10.1016/j.eclinm.2022.101783

[15] Zacharias HU, Dubey S, Koduri G, D’Cruz D. Rheumatological complications of COVID 19. Autoimmun Rev. 2021;20(9):102883. doi: 10.1016/j.autrev.2021.102883

[16] Zacharias H.U., Dubey S., Koduri G., D’Cruz D. Rheumatological complications of Covid 19 // Autoimmun Rev. 2021. Vol. 20, N. 9. P. 102883. doi: 10.1016/j.autrev.2021.102883

[17] Tang KT, Hsu BC, Chen DY. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013. doi: 10.3389/fimmu.2021.645013

[18] Tang K.T., Hsu B.C., Chen D.Y. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review // Front Immunol. 2021. Vol. 12. P. 645013. doi: 10.3389/fimmu.2021.645013

[19] Caso F, Costa L, Ruscitti P, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524. doi: 10.1016/j.autrev.2020.102524

[20] Caso F., Costa L., Ruscitti P., et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? // Autoimmun Rev. 2020. Vol. 19, N. 5. P. 102524. doi: 10.1016/j.autrev.2020.102524

[21] Bonometti R, Sacchi MC, Stobbione P, et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24(18):9695–9697. doi: 10.26355/eurrev_202009_23060

[22] Bonometti R., Sacchi M.C., Stobbione P., et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection // Eur Rev Med Pharmacol Sci. 2020. Vol. 24, N. 18. P. 9695–9697. doi: 10.26355/eurrev_202009_23060

[23] Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection – United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(40):1450–1456. doi: 10.15585/mmwr.mm6940e1

[24] Morris S.B., Schwartz N.G., Patel P., et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection – United Kingdom and United States, March-August 2020 // MMWR Morb Mortal Wkly Rep. 2020. Vol. 69, N. 40. P. 1450–1456. doi: 10.15585/mmwr.mm6940e1

[25] Berthelot JM, Drouet L, Lioté F. Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? Emerg Microbes Infect. 2020;9:1:1514–1522. doi: 10.1080/22221751.2020.1785336

[26] Berthelot J.M., Drouet L., Lioté F. Kawasaki-like diseases and thrombotic coagulopathy in COVID-19: delayed over-activation of the STING pathway? // Emerg Microbes Infect. 2020. Vol. 9, N. 1. P. 1514–1522. doi: 10.1080/22221751.2020.1785336

[27] Viner RM, Whittaker E. Kawasaki-like disease: Emerging complication during the COVID-19 pandemic. Lancet. 2020;395:1741–1743. doi: 10.1016/S0140-6736(20)31129-6

[28] Viner R.M., Whittaker E. Kawasaki-like disease: Emerging complication during the COVID-19 pandemic // Lancet. 2020. Vol. 395. P. 1741–1743. doi: 10.1016/S0140-6736(20)31129-6

[29] Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case .Hosp Pediatr. 2020;10(6):537–540. doi: 10.1542/hpeds.2020-0123

[30] Jones V.G., Mills M., Suarez D., et al. COVID-19 and Kawasaki disease: novel virus and novel case // Hosp Pediatr. 2020. Vol. 10, N. 6. P. 537–540. doi: 10.1542/hpeds.2020-0123

[31] Mazurov VI, Gaidukova IZ, Bakulin IG, et al. Patterns of COVID-19 infection course and factors of adverse prognosis in patients with immune-mediated inflammatory disease. RMJ. 2020;11:4–8. EDN: PVKYGE

[32] Мазуров В.И., Гайдукова И.З., Бакулин И.Г., и др. Особенности течения и факторы неблагоприятного прогноза коронавирусной инфекции COVID-19 у пациентов с иммуновоспалительными заболеваниями // РМЖ. 2020. № 11. С. 4–8. EDN: PVKYGE

[33] Azkur AK, Akdis M, Azkur D, et al. Immuneresponse to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–1581. doi: 10.1111/all.14364

[34] Azkur A.K., Akdis M., Azkur D., et al. Immuneresponse to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 // Allergy. 2020. Vol. 75, N. 7. P. 1564–1581. doi: 10.1111/all.14364

[35] Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020;217:108487. doi: 10.1016/j.clim.2020.108487

[36] Roncati L., Ligabue G., Fabbiani L., et al. Type 3 hypersensitivity in COVID-19 vasculitis // Clin Immunol. 2020. Vol. 217. P. 108487. doi: 10.1016/j.clim.2020.108487

[37] Nasonov EL, Baranov AA, Shilkina NP. Vasculitis and vasculopathy. Yaroslavl: Verkhnyaya Volga; 1999. 612 p. (In Russ.)

[38] Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999. 612 c.

[39] Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis. 1995;20(4):1010–1036. doi: 10.1093/clinids/20.4.1010

[40] Somer T., Finegold S.M. Vasculitides associated with infections, immunization, and antimicrobial drugs // Clin Infect Dis. 1995. Vol. 20, N. 4. P. 1010–1036. doi: 10.1093/clinids/20.4.1010

[41] Munoz-Grajales C, Pineda JC. Pathophysiological relationship between infections and systemic vasculitis. Autoimmune Dis. 2015;2015:286783. doi: 10.1155/2015/286783

[42] Munoz-Grajales C., Pineda J.C. Pathophysiological relationship between infections and systemic vasculitis // Autoimmune Dis. 2015. Vol. 2015. P. 286783. doi: 10.1155/2015/286783

[43] Goeijenbier M, van Wissen M, van de Weg C, et al. Viral infections and mechanisms of thrombosis andbleeding. J Med Virol. 2012;84(10):1680–1696. doi: 10.1002/jmv.23354

[44] Goeijenbier M., van Wissen M., van de Weg C., et al. Viral infections and mechanisms of thrombosis andbleeding // J Med Virol. 2012. Vol. 84, N. 10. P. 1680–1696. doi: 10.1002/jmv.23354

[45] Nasonov EL, Beketova TV, Reshetnyak TM, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated (autoimmune) inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Rheumatology Science and Practice. 2020;58(4):353–367. EDN: CTBEPP doi: 10.47360/1995-4484-2020-353-367

[46] Насонов Е.Л., Бекетова Т.В., Решетняк Т.М., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания: на перекрестке проблем тромбовоспаления и аутоиммунитета // Научно-практическая ревматология. 2020. Т. 58, № 4. С. 353–367. EDN: CTBEPP doi: 10.47360/1995-4484-2020-353-367

[47] Siddiqi HK, Libby P, Ridker PM. COVID-19 — a vascular disease. Trends Cardiovasc Med. 202;31(1):1–5. doi: 10.1016/j.tcm.2020.10.005

[48] Siddiqi H.K., Libby P., Ridker P.M. COVID-19 — a vascular disease // Trends Cardiovasc Med. 2021. Vol. 31, N. 1. P. 1–5. doi: 10.1016/j.tcm.2020.10.005

[49] Becker RC. COVID-19-associated vasculitis and vasculopathy. J Thromb Thrombolysis. 2020;50(3):499–511. doi: 10.1007/s11239-020-02230-4

[50] Becker R.C. COVID-19-associated vasculitis and vasculopathy // J Thromb Thrombolysis. 2020. Vol. 50, N. 3. P. 499–511. doi: 10.1007/s11239-020-02230-4

[51] Manenti A, Farinetti A, Manco G, Mattioli A. Vasculitis and aortitis: COVID-19 challenging complications. J Vasc Surg. 2021;73(1):347–348. doi: 10.1016/j.jvs.2020.08.029

[52] Manenti A., Farinetti A., Manco G., Mattioli A. Vasculitis and aortitis: COVID-19 challenging complications // J Vasc Surg 2021. Vol. 73, N. 1. P. 347–348. doi: 10.1016/j.jvs.2020.08.029

[53] Arcanjo A, Logullo J, Menezes CCB, et al. The emerging role of neutrophil extracellular traps insevere acute respiratory syndrome coronavirus 2 (COVID-19). Sci Rep. 2020;10(1):19630. doi: 10.1038/s41598-020-76781-0

[54] Arcanjo A., Logullo J., Menezes C.C.B., et al. The emerging role of neutrophil extracellular traps insevere acute respiratory syndrome coronavirus 2 (COVID-19) // Sci Rep. 2020. Vol. 10, N. 1. P. 19630. doi: 10.1038/s41598-020-76781-0

[55] Moretti M, Treppo E, Monti S, et al. Systemic vasculitis: one year in review 2023. Clin Exp Rheumatol. 2023;41(4):765–773. doi: 10.55563/clinexprheumatol/zf4daj

[56] Moretti M., Treppo E., Monti S., et al. Systemic vasculitis: one year in review 2023 // Clin Exp Rheumatol. 2023. Vol. 41, N. 4. P. 765–773. doi: 10.55563/clinexprheumatol/zf4daj

[57] Beketova TV, Popov IYu, Babak VV. Review of guideline for the management of ANCA-associated vasculitis, presented in 2021 by the American College of Rheumatology/Vasculitis Foundation. Rheumatology Science and Practice. 2021;59(6):684–692. EDN: WSBLPQ doi: 10.47360/1995-4484-2021-684-69

[58] Бекетова Т.В., Попов И.Ю., Бабак В.В. Обзор рекомендаций по лечению АНЦА-ассоциированных системных васкулитов, представленных в 2021 г. Американской коллегией ревматологов и Фондом васкулитов // Научно-практическая ревматология. 2021. Т. 59, № 6. С. 684–692. EDN: WSBLPQ doi: 10.47360/1995-4484-2021-684-69

[59] Magro CM, Crowson AN, Dawood M, Nuovo GJ. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J Rheumatol. 2002;29(6):1227–1235.

[60] Magro C.M., Crowson A.N., Dawood M., Nuovo G.J. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases // J Rheumatol. 2002. Vol. 29, N. 6. P. 1227–1235.

[61] Belov BS, Egorova ON, Tarasova GM, Muravyova NV. Infections and systemic vasculitis. Modern Rheumatology Journal. 2022;16(5):75–81. EDN: OFEMOT doi: 10.14412/1996-7012-2022-5-75-81

[62] Белов Б.С, Егорова О.Н, Тарасова Г.М, Муравьева Н.В. Инфекции и системные васкулиты // Современная ревматология. 2022. Т. 16, № 5. С. 75–81. EDN: OFEMOT doi: 10.14412/1996-7012-2022-5-75-81

[63] Uppal NN, Kello N, Shah HH, et al. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19. Kidney Int Rep. 2020;5(11):2079–2083. doi: 10.1016/j.ekir.2020.08.012

[64] Uppal N.N., Kello N., Shah H.H., et al. De novo ANCA-associated vasculitis with glomerulonephritis in COVID-19 // Kidney Int Rep. 2020. Vol. 5, N. 11. P. 2079–2083. doi: 10.1016/j.ekir.2020.08.012

[65] Jalalzadeh M, Valencia-Manrique JC, Boma N, et al. Antineutrophil cytoplasmic antibody-associated glomerulonephritis in a case of scleroderma after recent diagnosis with COVID-19. Cureus. 2021;13:e12485. doi: 10.7759/cureus.12485

[66] Jalalzadeh M., Valencia-Manrique J.C., Boma N., et al. Antineutrophil cytoplasmic antibody-associated glomerulonephritis in a case of scleroderma after recent diagnosis with COVID-19 // Cureus. 2021. Vol. 13. P. e12485. doi: 10.7759/cureus.12485

[67] Patel R, Amrutiya V, Baghal M, et al. Life-threatening diffuse alveolar hemorrhage as an initial presentation of microscopic polyangiitis: COVID-19 as a likely culprit. Cureus. 2021;13(4):e14403. doi: 10.7759/cureus.14403

[68] Patel R., Amrutiya V., Baghal M., et al. Life-threatening diffuse alveolar hemorrhage as an initial presentation of microscopic polyangiitis: COVID-19 as a likely culprit // Cureus. 2021. Vol. 13, N. 4. P. e14403. doi: 10.7759/cureus.14403

[69] Hussein A, Al Khalil K, Bawazir YM. Anti-neutrophilic cytoplasmicantibody (ANCA) vasculitis presented as pulmonary hemorrhage in apositive COVID-19 patient: a case report. Cureus. 2020;12(8):e9643. doi: 10.7759/cureus.9643

[70] Hussein A., Al Khalil K., Bawazir Y.M. Anti-neutrophilic cytoplasmicantibody (ANCA) vasculitis presented as pulmonary hemorrhage in apositive COVID-19 patient: a case report // Cureus. 2020. Vol. 12, N. 8. P. e9643. doi: 10.7759/cureus.9643

[71] Assar S, Pournazari M, Soufivand P, et al. Microscopic polyangiitis associated with coronavirus disease-2019 (COVID-19) infection in an elderly male. Egypt Rheumatol. 2021;43(3):225–228. doi: 10.1016/j.ejr.2021.03.001

[72] Assar S., Pournazari M., Soufivand P., et al. Microscopic polyangiitis associated with coronavirus disease-2019(COVID-19) infection in an elderly male // Egypt Rheumatol. 2021. Vol. 43, N. 3. P. 225–228. doi: 10.1016/j.ejr.2021.03.001

[73] Kawashima S, Kishimoto M, Hibino T, et al. MPO-ANCA-positive microscopic polyangiitis following COVID-19 infection. Intern Med. 2022;61:567–570. doi: 10.2169/internalmedicine.8615-21

[74] Kawashima S., Kishimoto M., Hibino T., et al. MPO-ANCA-positive microscopic polyangiitis following COVID-19 infection // Intern Med. 2022. Vol. 61. P. 567–570. doi: 10.2169/internalmedicine.8615-21

[75] Theofilis P, Vordoni A, Koukoulaki M, et al. Overview of infections as an etiologic factor and complication in patients with vasculitides. Rheumatol Int. 2022;42(5):759–770. doi: 10.1007/s00296-022-05100-9

[76] Theofilis P., Vordoni A., Koukoulaki M., et al. Overview of infections as an etiologic factor and complication in patients with vasculitides // Rheumatol Int. 2022. Vol. 42, N. 5. P. 759–770. doi: 10.1007/s00296-022-05100-9

[77] Ackermann M, Anders HJ, Bilyy R, et al. Patients with COVID-19: in the dark-NETs of neutrophils. Cell Death Differ. 2021;28(11):3125–3139. doi: 10.1038/s41418-021-00805-z

[78] Ackermann M., Anders H.J., Bilyy R., et al. Patients with COVID-19: in the dark-NETs of neutrophils // Cell Death Differ. 2021. Vol. 28, N. 11. P. 3125–3139. doi: 10.1038/s41418-021-00805-z

[79] Narasaraju T, Tang BM, Herrmann M, et al. Neutrophilia and netopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19. Front Pharmacol. 2020;11:870. doi: 10.3389/fphar.2020.00870

[80] Narasaraju T., Tang B.M., Herrmann M., et al. Neutrophilia and netopathy as key pathologic drivers of progressive lung impairment in patients with COVID-19 // Front Pharmacol. 2020. Vol. 11. P. 870. doi: 10.3389/fphar.2020.00870

[81] Kadkhoda K, Laurita K. Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients. Cell Death Discov. 2021;7:277. doi: 10.1038/s41420-021-00671-1

[82] Kadkhoda K., Laurita K. Antineutrophil cytoplasmic antibodies and their association with clinical outcomes in hospitalized COVID-19 patients // Cell Death Discov. 2021. Vol. 7. P. 277. doi: 10.1038/s41420-021-00671-1

[83] Lee LE, Jeong W, Park Y-B, et al. Clinical significance of antineutrophil cytoplasmic antibody positivity in patients infected with SARS-CoV-2. J Clin Med. 2022;11:4152. doi: 10.3390/jcm11144152

[84] Lee L.E., Jeong W., Park Y.-B., et al. Clinical significance of antineutrophil cytoplasmic antibody positivity in patients infected with SARS-CoV-2 // J Clin Med. 2022. Vol. 11. P. 4152. doi: 10.3390/jcm11144152

[85] Madanchi N, Stingo FE, Patrick KC, et al. Possible association between COVID-19 infection and de novo antineutrophil cytoplasmic antibody-associated vasculitis. Cureus. 2021;13(12):e20331. doi: 10.7759/cureus.20331

[86] Madanchi N., Stingo F.E., Patrick K.C., et al. Possible association between COVID-19 infection and de novo antineutrophil cytoplasmic antibody-associated vasculitis // Cureus. 2021. Vol. 13, N. 12. P. e20331. doi: 10.7759/cureus.20331

[87] Izci Duran T, Turkmen E, Dilek M, et al. ANCA-associated vasculitis after COVID-19. Rheumatol Int. 2021;41(8):1523–1529. doi: 10.1007/s00296-021-04914-3

[88] Izci Duran T., Turkmen E., Dilek M., et al. ANCA-associated vasculitis after COVID-19 // Rheumatol Int. 2021. Vol. 41, N. 8. P. 1523–1529. doi: 10.1007/s00296-021-04914-3

[89] Morris D, Patel K, Rahimi O, et al. ANCA vasculitis: A manifestation of Post-COVID-19 syndrome. Respir Med Case Rep. 2021;34:101549. doi: 10.1016/j.rmcr.2021.101549

[90] Morris D., Patel K., Rahimi O., et al. ANCA vasculitis: A manifestation of post-COVID-19 syndrome // Respir Med Case Rep. 2021. Vol. 34. P. 101549. doi: 10.1016/j.rmcr.2021.101549

[91] Jain A, Kaplan IAN, Al-Bermani T, et al. A case of microscopic poliangiitis (MPA) following SARS-COV-2 infections. Chest. 2022;162(4):A2237. doi: 10.1016/j.chest.2022.08.1851

[92] Jain A., Kaplan I.A.N., Al-Bermani T., et al. A case of microscopic poliangiitis (MPA) following SARS-COV-2 infections // Chest. 2022. Vol. 162, N. 4. P. A2237. doi: 10.1016/j.chest.2022.08.1851

[93] Allena N, Patel J, Nader G, et al. A rare case of SARS-CoV-2-induced microscopic polyangiitis. Cureus. 2021;13(5):e15259. doi: 10.7759/cureus.15259

[94] Allena N., Patel J., Nader G., et al. A rare case of SARS-CoV-2-induced microscopic polyangiitis // Cureus. 2021. Vol. 13, N. 5. P. e15259. doi: 10.7759/cureus.15259

[95] Weynand M, Raftakis I, Chérif MY, et al. A case of left foot drop as initial symptom of granulomatosis with polyangiitis: Triggered by COVID-19 disease? Clin Case Rep. 2022;10(10):e06418. doi: 10.1002/ccr3.6418

[96] Weynand M., Raftakis I., Chérif M.Y., et al. A case of left foot drop as initial symptom of granulomatosis with polyangiitis: Triggered by COVID-19 disease? // Clin Case Rep. 2022. Vol. 10, N. 10. P. e06418. doi: 10.1002/ccr3.6418

[97] Bressler MY, Pathak N, Cervellione K, et al. New onset granulomatosis with polyangiitis associated with COVID-19. Case Rep Dermatol Med. 2021;2021:8877292. doi: 10.1155/2021/8877292

[98] Bressler M.Y., Pathak N., Cervellione K., et al. New onset granulomatosis with polyangiitis associated with COVID-19 // Case Rep Dermatol Med. 2021. Vol. 2021. P. 8877292. doi: 10.1155/2021/8877292

[99] Abdulganieva DI, Shamsutdinova NG, Gaibaryan AA. COVID-19-associated angiitis: literature review and clinical case description. Modern Rheumatology Journal. 2022;16(1):73–76. EDN: SEQRNQ doi: 10.14412/1996-7012-2022-1-73-76

[100] Абдулганиева Д.И, Шамсутдинова Н.Г, Гайбарян А.А. COVID-19-ассоциированный ангиит: обзор литературы и описание клинического случая // Современная ревматология. 2022. Т. 16, № 1. С. 73–76. EDN: SEQRNQ doi: 10.14412/1996-7012-2022-1-73-76

RIGHTS & PERMISSIONS

Eco-Vector